ARS Pharmaceuticals, Inc. Advertising Expense
ARS Pharmaceuticals, Inc. (SPRY) reported Advertising Expense of $31.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AdvertisingExpense · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. advertising expense for the quarter ending 2026-06-30 was $31.00M, a 48.33% increase year-over-year.
- ARS Pharmaceuticals, Inc. advertising expense for the quarter ending 2026-03-31 was $36.30M, a 230.00% increase year-over-year.
- ARS Pharmaceuticals, Inc. advertising expense for the quarter ending 2025-12-31 was $27.00M, a 237.50% increase year-over-year.
- ARS Pharmaceuticals, Inc. advertising expense for the quarter ending 2025-09-30 was $40.90M, a 948.72% increase year-over-year.
- ARS Pharmaceuticals, Inc. advertising expense for fiscal 2025 was $99.80M, a 698.40% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. advertising expense for fiscal 2024 was $12.50M.
| Period end | Advertising Expense 3 month | Advertising Expense 6 month | Advertising Expense 9 month | Advertising Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.00M 10-Q · filed 2026-08-13 | $67.40M 10-Q · filed 2026-08-13 | $94.30M derived: sum of 3 quarters · filed 2026-08-13 | $135.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $36.30M 10-Q · filed 2026-05-15 | $63.30M derived: sum of 2 quarters · filed 2026-05-15 | $104.20M derived: sum of 3 quarters · filed 2026-05-15 | $125.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $67.90M derived: sum of 2 quarters · filed 2026-03-09 | $88.80M derived: sum of 3 quarters · filed 2026-08-13 | $99.80M 10-K · filed 2026-03-09 |
| 2025-09-30 | $40.90M 10-Q · filed 2025-11-10 | $61.80M derived: sum of 2 quarters · filed 2026-08-13 | $72.80M 10-Q · filed 2025-11-10 | $80.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $20.90M 10-Q · filed 2026-08-13 | $31.90M 10-Q · filed 2026-08-13 | $39.90M derived: sum of 3 quarters · filed 2026-08-13 | $43.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $11.00M 10-Q · filed 2026-05-15 | $19.00M derived: sum of 2 quarters · filed 2026-05-15 | $22.90M derived: sum of 3 quarters · filed 2026-05-15 | $22.90M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $11.90M derived: sum of 2 quarters · filed 2026-03-09 | $11.90M derived: sum of 3 quarters · filed 2026-03-09 | $12.50M 10-K · filed 2026-03-09 |
| 2024-09-30 | $3.90M 10-Q · filed 2025-11-10 | $3.90M derived: sum of 2 quarters · filed 2025-11-10 | $4.50M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |